What is Zacks Research’s Estimate for PRE Q2 Earnings?

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Zacks Research issued their Q2 2026 EPS estimates for Prenetics Global in a research report issued to clients and investors on Wednesday, June 10th. Zacks Research analyst B. Sorensen forecasts that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.77) per share. Zacks Research also issued estimates for Prenetics Global’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($1.58) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at $0.20 EPS, Q3 2027 earnings at $0.50 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $1.56 EPS.

A number of other equities analysts have also recently weighed in on PRE. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st. Lake Street Capital began coverage on shares of Prenetics Global in a research report on Monday, March 16th. They set a “buy” rating and a $29.00 price target on the stock. Finally, Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a research report on Monday, February 16th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Prenetics Global currently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Prenetics Global Stock Up 7.5%

Shares of NASDAQ PRE opened at $20.69 on Friday. The company’s fifty day moving average is $18.20 and its 200-day moving average is $17.83. The stock has a market cap of $349.12 million, a price-to-earnings ratio of -4.52 and a beta of 0.24. Prenetics Global has a twelve month low of $6.88 and a twelve month high of $23.63.

Prenetics Global announced that its Board of Directors has approved a share repurchase program on Friday, March 6th that authorizes the company to buyback $40.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 15.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Prenetics Global

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of Prenetics Global during the fourth quarter worth $1,302,000. 683 Capital Management LLC acquired a new stake in shares of Prenetics Global during the fourth quarter worth $1,181,000. Aberdeen Group plc acquired a new stake in shares of Prenetics Global during the third quarter worth $979,000. Millennium Management LLC acquired a new stake in shares of Prenetics Global during the fourth quarter worth $810,000. Finally, Marshall Wace LLP acquired a new stake in shares of Prenetics Global during the fourth quarter worth $788,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.